Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches

Part of paid clinical trials in Wichita, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT06582810
Status
Recruiting
Apply to this trial

Conditions

  • Headache
  • Subarachnoid; Hemorrhage, Nontraumatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage; 3. and report vasospasm prevalence in the cohort. Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.

Key Dates

Start date
Jan 31, 2025
Status verified
Jul 2025
Primary completion
Oct 31, 2027
Completion
Jul 31, 2028

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: Lidocaine infusion
    Patients will receive a 100 mg intravenous lidocaine bolus followed by an initial infusion at a rate of 2 mg∙kg -1∙h-1 based on ideal body weight. Lidocaine infusions will continue for a minimum of 1 h post-bolus. If headache numeric pain score decreases at all after initiation of infusion, then the rate will drop to 1 mg∙kg -1∙h-1. If headache numeric pain score starts increasing again, then the rate will return to 2 mg∙kg -1∙h-1, otherwise it will remain at 1 mg∙kg -1∙h-1 for up to 48 h.

Primary Outcome Measure

Reduction of pain [ Time Frame: Benefit should be seen within first 24 h of infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ascension Via Christi St. FrancisWichitaKansas67214
William L Krogman, MS
[email protected]
316-268-6156
Fernando Salgado, MD
[email protected]

Find similar trials in Wichita, KS

By research site
Ascension Via Christi St. Francis· Wichita, KS

Related Studies